Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NMT1 | P30419 | 5/20 | 0.42 |
| ▸ | NMT2 | O60551 | 4/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22247624 | 1.00 | KMT2A (0.43) | KMT2ANMT1NMT2SLC6A5TLR2 | |
| SCHEMBL22228935 | 1.00 | KMT2A (0.43) | KMT2ANMT1NMT2SLC6A5TLR2 | |
| SCHEMBL16010862 | 0.98 | FOLH1 (0.41) | KMT2ANMT1NMT2SLC6A5TLR2 | |
| SCHEMBL18396048 | 0.98 | FOLH1 (0.41) | KMT2ANMT1NMT2SLC6A5TLR2 | |
| SCHEMBL16010863 | 0.98 | FOLH1 (0.41) | KMT2ANMT1NMT2SLC6A5TLR2 | |
| SCHEMBL30031700 | 0.98 | FOLH1 (0.41) | KMT2ANMT1NMT2SLC6A5TLR2 | |
| SCHEMBL18396046 | 0.98 | FOLH1 (0.41) | KMT2ANMT1NMT2SLC6A5TLR2 | |
| SCHEMBL28950004 | 0.94 | FOLH1 (0.48) | SLC6A5TLR2FOLH1NOD1GLP1R | |
| SCHEMBL23780010 | 0.93 | EPHX2 (0.38) | KMT2ASLC6A5FOLH1TDP1POLB | |
| SCHEMBL23780008 | 0.93 | EPHX2 (0.38) | KMT2ASLC6A5FOLH1TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140971-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSTY | 2024-05-02 | — | — | US | disclosed |
| US-20200231614-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY | 2020-07-23 | — | — | US | disclosed |
| US-20200231614-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY | 2020-07-23 | — | — | US | disclosed |
| WO-2017070482-A2 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070482-A2 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231614-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | PSMA7, PSMA6, PSMA1 | KMT2A 2165/4885NMT1 406/4885NMT2 827/4885 |
| US-20240140971-A1 | PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY | PSMA3, PSMA6, PSMA7 | KMT2A 2745/4885NMT1 245/4885NMT2 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.